Evidence map›Paper›PMID 31123819›Full record

Observational studyHeart and vessels2019

Responses of prothrombin time and activated partial thromboplastin time to edoxaban in Japanese patients with non-valvular atrial fibrillation: characteristics of representative reagents in Japan (CVI ARO 7).

Shinya Suzuki, Yoshiyuki Morishima, Atsushi Takita, Naoharu Yagi, Takayuki Otsuka, Takuto Arita, Takeshi Yamashita

Erratum issuedAbstract readComparative StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Heart and vessels, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shinya SuzukiDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishi-azabu, Minato-ku, Tokyo, 106-0031, Japan. sinsuz-tky@umin.net.ORCID http://orcid.org/0000-0002-4769-5925
Yoshiyuki MorishimaMedical Science Department, Daiichi Sankyo Co., Ltd, Tokyo, Japan.
Atsushi TakitaSafety and Risk Management Department, Daiichi Sankyo Co., Ltd, Tokyo, Japan.
Naoharu YagiDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishi-azabu, Minato-ku, Tokyo, 106-0031, Japan.
Takayuki OtsukaDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishi-azabu, Minato-ku, Tokyo, 106-0031, Japan.
Takuto AritaDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishi-azabu, Minato-ku, Tokyo, 106-0031, Japan.
Takeshi YamashitaDepartment of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishi-azabu, Minato-ku, Tokyo, 106-0031, Japan.
Cardiovascular Institute Hospital · JPDaiichi-Sankyo (Japan) · JP

Funding

Daiichi-Sankyo (JP) Research funding
6 · The paper itself

Abstract

The aims of this study were to determine the distribution of plasma concentration of edoxaban (PC-Ed) with their 90% interval (on therapy range) and its correlation with anticoagulation markers in patients with non-valvular atrial fibrillation (NVAF). Consecutive 97 NVAF patients under edoxaban therapy were evaluated (60/30 mg dose, n = 48/49; men/women, n = 71/26; age, 69 years). CHADS

Indexed as

Administration, OralAgedAtrial FibrillationBiomarkersDose-Response Relationship, DrugFactor Xa InhibitorsFemaleFollow-Up StudiesHumansIncidenceJapanMalePartial Thromboplastin TimePredictive Value of TestsProspective StudiesProthrombin TimeBiomarkersedoxabanFactor Xa InhibitorsPyridinesThiazolesAnticoagulationAtrial fibrillationEdoxaban

Identifiers

PMID31123819
OpenAlexW2945715339

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.